SK9532003A3 - Crystalline forms of atorvastatin calcium - Google Patents

Crystalline forms of atorvastatin calcium Download PDF

Info

Publication number: SK9532003A3
Authority: SK; Slovakia
Prior art keywords: intensity; polymorphic form; crystalline polymorphic; calcium; atorvastatin calcium
Prior art date: 2000-12-27

Application number

SK953-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Der Schaaf Paul Adriaan Van

Fritz Blatter

Martin Szelagiewicz

Kai-Uwe Schoning

Original Assignee

Ciba Sc Holding Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-27

Filing date

2001-12-19

Publication date

2004-04-06

2001-12-19 Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag

2004-04-06 Publication of SK9532003A3 publication Critical patent/SK9532003A3/sk

Links

OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 39
229960001770 atorvastatin calcium Drugs 0.000 title claims abstract description 35
238000002360 preparation method Methods 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 25
239000000725 suspension Substances 0.000 claims description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 18
159000000007 calcium salts Chemical class 0.000 claims description 17
239000000843 powder Substances 0.000 claims description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
239000003960 organic solvent Substances 0.000 claims description 15
-1 (phenylamino) carbonyl Chemical group 0.000 claims description 10
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 9
OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 claims description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
239000000920 calcium hydroxide Substances 0.000 claims description 2
229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
238000000634 powder X-ray diffraction Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
238000002441 X-ray diffraction Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 5
229960005370 atorvastatin Drugs 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
150000003863 ammonium salts Chemical class 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
VVRPOCPLIUDBSA-CNZCJKERSA-M sodium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Na+].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 VVRPOCPLIUDBSA-CNZCJKERSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK953-2003A 2000-12-27 2001-12-19 Crystalline forms of atorvastatin calcium SK9532003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00811249		2000-12-27
PCT/EP2001/015012 WO2002051804A1 (en)	2000-12-27	2001-12-19	Crystalline forms of atorvastatin

Publications (1)

Publication Number	Publication Date
SK9532003A3 true SK9532003A3 (en)	2004-04-06

Family

ID=8175112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK953-2003A SK9532003A3 (en)	2000-12-27	2001-12-19	Crystalline forms of atorvastatin calcium

Country Status (23)

Country	Link
US (4)	US7538136B2 (cs)
EP (2)	EP2000461A1 (cs)
JP (2)	JP2004516311A (cs)
KR (1)	KR100790766B1 (cs)
CN (1)	CN1273449C (cs)
AT (1)	ATE420070T1 (cs)
AU (1)	AU2002224952B2 (cs)
CA (7)	CA2431068C (cs)
CZ (1)	CZ20032019A3 (cs)
DE (1)	DE60137364D1 (cs)
ES (1)	ES2319870T3 (cs)
HR (1)	HRP20030607A2 (cs)
HU (1)	HUP0302519A3 (cs)
IL (1)	IL156280A0 (cs)
IS (1)	IS6859A (cs)
MX (1)	MXPA03005879A (cs)
NO (1)	NO20032758D0 (cs)
NZ (1)	NZ527048A (cs)
PL (1)	PL365312A1 (cs)
PT (1)	PT1345896E (cs)
SK (1)	SK9532003A3 (cs)
WO (1)	WO2002051804A1 (cs)
ZA (1)	ZA200304297B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
CN1535139A (zh) *	2000-11-03	2004-10-06	��ҩ��ҵ��޹�˾	阿伐他丁半钙形式ⅶ
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) *	2000-12-27	2008-06-10	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of atorvastatin
HUP0400381A2 (hu)	2001-06-29	2004-09-28	Warner-Lambert Company Llc	[R-(R,R)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
JP2005500351A (ja) *	2001-07-30	2005-01-06	ドクター・レディーズ・ラボラトリーズ・リミテッド	結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
CA2450820C (en) *	2001-08-16	2011-03-15	Teva Pharmaceutical Industries Ltd.	Processes for preparing calcium salt forms of statins
US7563911B2 (en) *	2001-08-31	2009-07-21	Morepen Laboratories Ltd.	Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) *	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
PL372303A1 (en) *	2002-02-15	2005-07-11	Teva Pharmaceutical Industries Ltd.	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4422488B2 (ja)	2002-02-19	2010-02-24	テバファーマシューティカルインダストリーズリミティド	アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
WO2004022053A1 (en) *	2002-09-03	2004-03-18	Morepen Laboratories Limited	Atorvastatin calcium form vi or hydrates thereof
EP1572643A2 (en) *	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Crystalline form F of Atorvastatin hemi-calcium salt
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
CA2560252C (en)	2004-03-17	2009-08-04	Ranbaxy Laboratories Limited	Process for the production of atorvastatin calcium in amorphous form
EP1761489A1 (en) *	2004-03-17	2007-03-14	Ranbaxy Laboratories Limited	Crystalline form of atorvastatin hemi calcium
EP3581564A1 (en) *	2004-05-05	2019-12-18	Pfizer Products Inc.	Diethylamine salt forms of [r-(r,r)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
EP1767625A4 (en)	2004-06-11	2007-12-05	Ginkgo Biomedical Res Inst Co	ACTIVITY REGULATOR FOR INTERFERON-PRODUCING CELL
WO2006008091A2 (en) *	2004-07-16	2006-01-26	Lek Pharmaceuticals D.D.	Oxidative degradation products of atorvastatin calcium
CA2754932C (en) *	2004-07-20	2014-04-01	Warner-Lambert Company Llc	Novel forms of [r-(r,r)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
MX2007004722A (es)	2004-10-28	2007-06-15	Warner Lambert Co	Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2499047A1 (en) *	2005-03-01	2006-09-01	Apotex Pharmachem Inc.	Process for producing atorvastatin hemicalcium
JP5523699B2 (ja) *	2005-04-08	2014-06-18	エギシュヂョヂセルヂャールニルヴァーノサンミケデレースヴェーニタールササーグ	新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
CA2547216A1 (en)	2005-09-21	2007-03-21	Renuka D. Reddy	Process for annealing amorphous atorvastatin
ES2304335T3 (es)	2005-11-21	2010-05-19	Warner-Lambert Company Llc	Formas nuevas del acido (r-(r,r))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
US8080672B2 (en)	2005-12-13	2011-12-20	Teva Pharmaceutical Industries Ltd.	Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising amorphous atorvastatin
BRPI0702900A2 (pt) *	2006-06-28	2011-03-15	Teva Pharma	formas cristalinas da atorvastatina
EP2185527A2 (en) *	2007-07-11	2010-05-19	Actavis Group PTC EHF	Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) *	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) *	2015-07-23	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) *	2016-07-04	2019-10-03	ゼリア新薬工業株式会社	１，５−ベンゾジアゼピン化合物カルシウム塩の製造法
WO2025147589A1 (en)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ES2133158T3 (es) *	1993-01-19	1999-09-01	Warner Lambert Co	Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
BR9609872A (pt) *	1995-07-17	1999-03-23	Warner Lambert Co	Hemi sal de cálcio de ácido (R-(RR)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
HRP960313B1 (en)	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI1535613T1 (sl) *	1999-11-17	2010-12-31	Teva Pharma	Postopek za pripravo polimorfne oblike atorvastatin kalcija
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
EP1242373B1 (en)	1999-12-17	2006-03-15	Pfizer Science and Technology Ireland Limited	A process for producing crystalline atorvastatin calcium
CN1535139A (zh) *	2000-11-03	2004-10-06	��ҩ��ҵ��޹�˾	阿伐他丁半钙形式ⅶ
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) *	2000-12-27	2008-06-10	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of atorvastatin
WO2002057228A1 (en)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatin calcium
WO2002057229A1 (en) *	2001-01-19	2002-07-25	Biocon India Limited	FORM V CRYSTALLINE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl)	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
HUP0400381A2 (hu) *	2001-06-29	2004-09-28	Warner-Lambert Company Llc	[R-(R,R)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
JP2005500351A (ja) *	2001-07-30	2005-01-06	ドクター・レディーズ・ラボラトリーズ・リミテッド	結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム

2001
- 2001-12-19 CA CA002431068A patent/CA2431068C/en not_active Expired - Fee Related
- 2001-12-19 US US10/130,197 patent/US7538136B2/en not_active Expired - Fee Related
- 2001-12-19 EP EP08016057A patent/EP2000461A1/en not_active Withdrawn
- 2001-12-19 EP EP01994809A patent/EP1345896B1/en not_active Expired - Lifetime
- 2001-12-19 CA CA002622477A patent/CA2622477A1/en not_active Abandoned
- 2001-12-19 DE DE60137364T patent/DE60137364D1/de not_active Expired - Fee Related
- 2001-12-19 AU AU2002224952A patent/AU2002224952B2/en not_active Ceased
- 2001-12-19 CN CNB018215017A patent/CN1273449C/zh not_active Expired - Fee Related
- 2001-12-19 WO PCT/EP2001/015012 patent/WO2002051804A1/en not_active Ceased
- 2001-12-19 CA CA002622697A patent/CA2622697A1/en not_active Abandoned
- 2001-12-19 NZ NZ527048A patent/NZ527048A/xx unknown
- 2001-12-19 CA CA002623600A patent/CA2623600A1/en not_active Abandoned
- 2001-12-19 IL IL15628001A patent/IL156280A0/xx not_active IP Right Cessation
- 2001-12-19 ES ES01994809T patent/ES2319870T3/es not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005879A patent/MXPA03005879A/es active IP Right Grant
- 2001-12-19 CA CA002622727A patent/CA2622727A1/en not_active Abandoned
- 2001-12-19 CA CA002623599A patent/CA2623599A1/en not_active Abandoned
- 2001-12-19 HU HU0302519A patent/HUP0302519A3/hu unknown
- 2001-12-19 CZ CZ20032019A patent/CZ20032019A3/cs unknown
- 2001-12-19 CA CA002626317A patent/CA2626317A1/en not_active Abandoned
- 2001-12-19 PT PT01994809T patent/PT1345896E/pt unknown
- 2001-12-19 SK SK953-2003A patent/SK9532003A3/sk unknown
- 2001-12-19 PL PL01365312A patent/PL365312A1/xx not_active Application Discontinuation
- 2001-12-19 KR KR1020037008685A patent/KR100790766B1/ko not_active Expired - Fee Related
- 2001-12-19 JP JP2002552901A patent/JP2004516311A/ja not_active Withdrawn
- 2001-12-19 HR HR20030607A patent/HRP20030607A2/hr not_active Application Discontinuation
- 2001-12-19 AT AT01994809T patent/ATE420070T1/de not_active IP Right Cessation
2003
- 2003-06-02 ZA ZA200304297A patent/ZA200304297B/en unknown
- 2003-06-17 NO NO20032758A patent/NO20032758D0/no not_active Application Discontinuation
- 2003-06-24 IS IS6859A patent/IS6859A/is unknown
2004
- 2004-06-02 US US10/860,084 patent/US20040220255A1/en not_active Abandoned
2006
- 2006-05-09 US US11/431,184 patent/US20060205805A1/en not_active Abandoned
2009
- 2009-04-17 US US12/386,413 patent/US20090281162A1/en not_active Abandoned
- 2009-05-27 JP JP2009127757A patent/JP2009221216A/ja active Pending

Also Published As

Publication number	Publication date
JP2009221216A (ja)	2009-10-01
US20030114686A1 (en)	2003-06-19
CA2431068C (en)	2008-06-10
NO20032758L (no)	2003-06-17
NZ527048A (en)	2004-12-24
NO20032758D0 (no)	2003-06-17
EP1345896A1 (en)	2003-09-24
IS6859A (is)	2003-06-24
MXPA03005879A (es)	2003-09-10
ES2319870T3 (es)	2009-05-14
ZA200304297B (en)	2004-08-16
DE60137364D1 (de)	2009-02-26
CA2623599A1 (en)	2002-07-04
EP2000461A1 (en)	2008-12-10
EP1345896B1 (en)	2009-01-07
CA2623600A1 (en)	2002-07-04
CN1273449C (zh)	2006-09-06
ATE420070T1 (de)	2009-01-15
CA2622697A1 (en)	2002-07-04
US20060205805A1 (en)	2006-09-14
PT1345896E (pt)	2009-02-19
HUP0302519A2 (hu)	2003-12-29
US20090281162A1 (en)	2009-11-12
CN1483022A (zh)	2004-03-17
CA2622477A1 (en)	2002-07-04
KR100790766B1 (ko)	2008-01-03
KR20030064880A (ko)	2003-08-02
CA2626317A1 (en)	2002-07-04
JP2004516311A (ja)	2004-06-03
HRP20030607A2 (en)	2005-06-30
WO2002051804A1 (en)	2002-07-04
PL365312A1 (en)	2004-12-27
HUP0302519A3 (en)	2008-10-28
CZ20032019A3 (cs)	2003-10-15
CA2622727A1 (en)	2002-07-04
CA2431068A1 (en)	2002-07-04
AU2002224952B2 (en)	2007-04-05
US20040220255A1 (en)	2004-11-04
US7538136B2 (en)	2009-05-26
IL156280A0 (en)	2004-01-04

Legal Events

Date	Code	Title	Description
2010-10-07	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
KR100790766B1 (ko)	2008-01-03	아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2002224952A1 (en)	2003-01-23	Crystalline forms of atorvastatin
SK7212003A3 (en)	2004-03-02	Hydrolysis of [R(R,R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
SK391091A3 (en)	2000-10-09	Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
KR20120139763A (ko)	2012-12-27	랄테그라비어 염 및 이의 결정형
EP2049479A2 (en)	2009-04-22	Polymorphs of atorvastatin sodium and magnesium salts
US20040063961A1 (en)	2004-04-01	Crystalline forms of cerivastatin sodium
SK50632006A3 (sk)	2006-09-07	Spôsob prípravy hemivápenatej soli (E)-7-[4-(4-fluórfenyl)-6- izopropyl-2-[metyl(metylsulfonyl)amino]pyrimidín-5-yl](3R,5S)- 3,5-dihydroxy-6-hepténovej kyseliny
IL186221A (en)	2011-11-30	Crystalline rosuvastatin intermediate
EP1732886B1 (en)	2010-03-03	Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
CN1902194B (zh)	2011-04-20	制备非晶态(4r-顺)-6-[2-[3-苯基-4-(苯基氨基甲酰基)-2-(4-氟苯基)-5-(1-甲基乙基)-吡咯-1-基]-乙基]-2,2-二甲基-[1,3]-二噁烷-4-基-乙酸的方法